SEC Form 4 · accession 0000904454-18-000275
Paratek Pharmaceuticals, Inc. · PRTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam Woodrow
Officer — VP & Chief Commercial Officer
Period of report
Apr 3, 2018
Accepted (ET)
Apr 5, 2018 · 6:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178711
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 3, 2018 | A | 14,250 | $0.00 | A | 94,867 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents performance-based restricted stock units granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on April 3, 2018.